May 7 2020 - Even After FDA Approval Market Keeps Underestimating Gilead's Antiviral
Summary The market is schizophrenic about Remdesivir. Hints of its approval lift the entire market. There are hopeful signals out of U.S. practitione...
Summary The market is schizophrenic about Remdesivir. Hints of its approval lift the entire market. There are hopeful signals out of U.S. practitione...
Summary Gilead Sciences has an impressive portfolio of assets, but its brand is quickly becoming better known as a result of its COVID-19 drug. Out...
Summary Gilead wouldn't give the details the market wanted regarding the remdesivir business model on the recent earnings call. Its recent update c...
LONDON/WASHINGTON (Reuters) - Hackers linked to Iran have targeted staff at U.S. drugmaker Gilead Sciences Inc in recent weeks, according to publicly-...
Summary Gilead stock surged significantly after my buy recommendation in December as a consequence of Remdesivir's potential to treat COVID-19. I f...
Summary GILD surged to Friday on the leak that University of Chicago Medicine's head researcher in GILD COVID studies reported that GILD's RDV ...
Summary Clearly it's good news that Gilead's remdesivir appears to have some effect against Covid-19 and that will be good for the stock. However, ...
Summary Gilead Sciences is a franchise biopharmaceutical company worthy of both investment and speculation. There is particular speculative opportu...